Randomised controlled trial of the effect of long-term selenium supplementation on plasma cholesterol in an elderly Danish population

British Journal of Nutrition

Volumn 114, Issue 11, 2015, Pages 1807-1818

  Cold, Frederik ^a   Winther, Kristian H ^a   Pastor Barriuso, Roberto ^b   Rayman, Margaret P ^c   Guallar, Eliseo ^d   Nybo, Mads ^a   Griffin, Bruce A ^c   Stranges, Saverio ^e,f   Cold, Soren ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c UNIVERSITY OF SURREY   (United Kingdom)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^f UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Cholesterol; CVD; Lipids; Randomised controlled trials; Selenium; Selenium supplementation

Indexed keywords

CHOLESTEROL; PLACEBO; SELENIUM; HYPOCHOLESTEROLEMIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER PREVENTION; CELL VIABILITY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DANISH CITIZEN; DENMARK; DOUBLE BLIND PROCEDURE; ELDERLY CARE; FEASIBILITY STUDY; FEMALE; GROOVED NAIL; HAIR LOSS; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINERAL SUPPLEMENTATION; NAIL DISEASE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SELENIUM BLOOD LEVEL; SKIN MANIFESTATION; SMOKING; UNITED KINGDOM; ADVERSE EFFECTS; BLOOD; CARDIOVASCULAR DISEASES; CHEMISTRY; DEFICIENCY; DIET THERAPY; DIETARY SUPPLEMENT; DRIED YEAST; EPIDEMIOLOGY; GERIATRIC NUTRITION; INTENTION TO TREAT ANALYSIS; LONGITUDINAL STUDY; NUTRITIONAL DEFICIENCY; PATHOPHYSIOLOGY; PATIENT DROPOUT; RISK FACTOR; TIME FACTOR;

AGED; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL; CROSS-SECTIONAL STUDIES; DEFICIENCY DISEASES; DENMARK; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; ELDER NUTRITIONAL PHYSIOLOGICAL PHENOMENA; FEASIBILITY STUDIES; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PATIENT DROPOUTS; RISK FACTORS; SELENIUM; TIME FACTORS; YEAST, DRIED;

EID: 84949318900     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114515003499     Document Type: Article

References (58)

1. Kryukov GV, Castellano S, Novoselov SV, et al. (2003) Characterization of mammalian selenoproteomes. Science 300, 1439-1443.
2. Rayman MP (2012) Selenium and human health. Lancet 379, 1256-1268.
3. Salonen JT, Alfthan G, Huttunen JK, et al. (1982) Association between cardiovascular death and myocardial infarction and serum selenium in a matched-pair longitudinal study. Lancet 2, 175-179.
4. Anonymous (1979) Observations on effect of sodium selenite in prevention of Keshan disease. Chin Med J (Engl) 92, 471-476.
5. Salonen JT, Salonen R, Seppänen K, et al. (1988) Relationship of serum selenium and antioxidants to plasma lipoproteins, platelet aggregability and prevalent ischaemic heart disease in Eastern Finnish men. Atherosclerosis 70, 155-160.
6. Sattler W, Maiorino M & Stocker R (1994) Reduction of HDL-and LDL-associated cholesterylester and phospholipid hydroperoxides by phospholipid hydroperoxide glutathione peroxidase and Ebselen (PZ 51). Arch Biochem Biophys 309, 214-221.
7. Blankenberg S, Rupprecht HJ, Bickel C, et al. (2003) Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl J Med 349, 1605-1613.
8. Brigelius-Flohe R, Banning A & Schnurr K (2003) Seleniumdependent enzymes in endothelial cell function. Antioxid Redox Signal 5, 205-215.
9. Curran JE, Jowett JB, Elliott KS, et al. (2005) Genetic variation in selenoprotein S influences inflammatory response. Nat Genet 37, 1234-1241.
10. Gao Y, Hannan NR, Wanyonyi S, et al. (2006) Activation of the selenoprotein SEPS1 gene expression by pro-inflammatory cytokines in HepG2 cells. Cytokine 33, 246-251.
11. Vunta H, Davis F, Palempalli UD, et al. (2007) The antiinflammatory effects of selenium are mediated through 15-deoxy-Delta12,14-prostaglandin J2 in macrophages. J Biol Chem 282, 17964-17973.
12. Flores-Mateo G, Navas-Acien A, Pastor-Barriuso R, et al. (2006) Selenium and coronary heart disease: A meta-analysis. Am J Clin Nutr 84, 762-773.
13. Stranges S, Marshall JR, Trevisan M, et al. (2006) Effects of selenium supplementation on cardiovascular disease incidence and mortality: secondary analyses in a randomized clinical trial. Am J Epidemiol 163, 694-699.
14. Stranges S, Navas-Acien A, Rayman MP, et al. (2010) Selenium status and cardiometabolic health: state of the evidence. Nutr Metab Cardiovasc Dis 20, 754-760.
15. Bjelakovic G, Nikolova D, Gluud LL, et al. (2012) Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev 3, CD007176.
16. Rees K, Hartley L, Day C, et al. (2013) Selenium supplementation for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 1, CD009671.
17. Stamler J, Wentworth D & Neaton JD (1986) Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 256, 2823-2828.
18. Prospective Studies Collaboration, Lewington S, Whitlock G, et al. (2007) Blood cholesterol and vascular mortality by age, sex and blood pressure: A meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths. Lancet 370, 1829-1839.
19. Jossa F, Trevisan M, Krogh V, et al. (1991) Serum selenium and coronary heart disease risk factors in southern Italian men. Atherosclerosis 87, 129-134.
20. Suadicani P, Hein HO & Gyntelberg F (1992) Serum selenium concentration and risk of ischaemic heart disease in a prospective cohort study of 3000 males. Atherosclerosis 96, 33-42.
21. Gámez C, Ruiz-López D, Artacho R, et al. (1997) Serum selenium in institutionalized elderly subjects and relation to other nutritional markers Letter). Clin Chem 43, 693-694.
22. Coudray C, Roussel AM, Mainard F, et al. (1997) Lipid peroxidation level and antioxidant micronutrient status in a pre-aging population; correlation with chronic disease prevalence in a French epidemiological study (Nantes, France). J Am Coll Nutr 16, 584-591.
23. Bates CJ, Thane CW, Prentice A, et al. (2002) Selenium status and its correlates in a British national diet and nutrition survey: people aged 65 years and over. J Trace Elem Med Biol 16, 1-8.
24. Bleys J, Navas-Acien A, Stranges S, et al. (2008) Serum selenium and serum lipids in US adults. Am J Clin Nutr 88, 416-423.
25. Laclaustra M, Stranges S, Navas-Acien A, et al. (2010) Serum selenium and serum lipids in US adults: National Health and Nutrition Examination Survey (NHANES) 2003-2004. Atherosclerosis 210, 643-648.
26. Stranges S, Laclaustra M, Ji C, et al. (2010) Higher selenium status is associated with adverse blood lipid profile in British adults. J Nutr 140, 81-87.
27. Yang KC, Lee LT, Lee YS, et al. (2010) Serum selenium concentration is associated with metabolic factors in the elderly: A cross-sectional study. Nutr Metab (Lond) 7, 38.
28. Stranges S, Tabak AG, Guallar E, et al. (2011) Selenium status and blood lipids: The cardiovascular risk in Young Finns study. J Intern Med 270, 469-477.
29. Stranges S, Galletti F, Farinaro E, et al. (2011) Associations of selenium status with cardiometabolic risk factors: an 8-year follow-up analysis of the Olivetti Heart study. Atherosclerosis 217, 274-278.
30. Clark LC, Combs GF Jr, Turnbull BW, et al. (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276, 1957-1963.
31. Levander OA, Alfthan G, Arvilommi H, et al. (1983) Bioavailability of selenium to Finnish men as assessed by platelet glutathione peroxidase activity and other blood parameters. Am J Clin Nutr 37, 887-897.
32. Rayman MP, Stranges S, Griffin BA, et al. (2011) Effect of supplementation with high-selenium yeast on plasma lipids. A randomized trial. Ann Intern Med 154, 656-665.
33. Luoma PV, Korpela H, Sotaniem EA, et al. (1985) Serum selenium, glutathione peroxidase, lipids, and human liver microsomal enzyme activity. A double-blind controlled trial of selenium supplementation. Biol Trace Elem Res 8, 113-121.
34. Yu SY, Mao BL, Xiao P, et al. (1990) Intervention trial with selenium for the prevention of lung cancer among tin miners in Yunnan, China. A pilot study. Biol Trace Elem Res 24, 105-108.
35. Meltzer HM, Mundal HH, Alexander J, et al. (1994) Does dietary arsenic and mercury affect cutaneous bleeding time and blood lipids in humans? Biol Trace Elem Res 46, 135-153.
36. Meltzer HM, Folmer M, Wang S, et al. (1997) Supplementary selenium influences the response to fatty acid-induced oxidative stress in humans. Biol Trace Elem Res 60, 51-68.
37. Ravn-Haren G, Bugel S, Krath BN, et al. (2008) A short-term intervention trial with selenate, selenium-enriched yeast and selenium-enriched milk: effects on oxidative defence regulation. Br J Nutr 99, 883-892.
38. Hawkes WC & Laslett LJ. (2009) Selenium supplementation does not improve vascular responsiveness in healthy North American men. Am J Physiol Heart Circ Physiol 296, H256-H262.
39. Wu J, Salisbury C, Graham R, et al. (2009) Increased consumption of wheat biofortified with selenium does not modify biomarkers of cancer risk, oxidative stress, or immune function in healthy Australian males. Environ Mol Mutagen 50, 489-501.
40. Larsen EH, Hansen M, Paulin H, et al. (2004) Speciation and bioavailability of selenium in yeast-based intervention agents used in cancer chemoprevention studies. J AOAC Int 87, 225-232.
41. Albert PS (1999) Longitudinal data analysis (repeated measures) in clinical trials. Stat Med 18, 1707-1732.
42. Diggle PJ, Heagerty P, Liang KY, et al. (2002) Analysis of Longitudinal Data, 2nd ed. Oxford: Oxford University Press.
43. Stender S, Dyerberg J, Bysted A, et al. (2006) A trans world journey. Atheroscler Suppl 7, 47-52.
44. Van Poppel G (1998) Intake of trans fatty acids in western Europe: The TRANSFAIR study. Lancet 351, 1099.
45. Langsted A, Freiberg JJ, Tybjaerg-Hansen A, et al. (2011) Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: The Copenhagen City Heart Study with 31 years of follow-up. J Intern Med 270, 65-75.
46. Unal B, Critchley JA & Capewell S. (2005) Modelling the decline in coronary heart disease deaths in England and Wales, 1981-2000: comparing contributions from primary prevention and secondary prevention. BMJ 331, 614.
47. Rasmussen LB, Carlé A, Jørgensen T, et al. (2008) Iodine intake before and after mandatory iodization in Denmark: results from the Danish Investigation of Iodine Intake and Thyroid Diseases (DanThyr) study. Br J Nutr 100, 166-173.
48. Haas V, Marley M, Green A, et al. (1988) Urinary iodine excretion in a geographically stratified Danish population sample not affected by iodination programmes. A change towards higher values. Acta Endocrinol (Copenh) 119, 125-131.
49. Zhao SJ, Ye Y, Sun FJ, et al. (2011) The impact of dietary iodine intake on lipid metabolism in mice. Biol Trace Elem Res 142, 581-588.
50. Jung CH, Sung KC, Shin HS, et al. (2003) Thyroid dysfunction and their relation to cardiovascular risk factors such as lipid profile, hsCRP, and waist hip ratio in Korea. Korean J Intern Med 18, 146-153.
51. Zimmermann MB, Aeberli I, Melse-Boonstra A, et al. (2009) Iodine treatment in children with subclinical hypothyroidism due to chronic iodine deficiency decreases thyrotropin and C-peptide concentrations and improves the lipid profile. Thyroid 19, 1099-1104.
52. Winther KH, Bonnema SJ, Cold F, et al. (2015) Does selenium supplementation affect thyroid function? Results from a randomized, controlled, double-blinded trial in a Danish population. Eur J Endocrinol 172, 657-667.
53. Duntas LH & Brenta G. (2012) The effect of thyroid disorders on lipid levels and metabolism. Med Clin North Am 96, 269-281.
54. Sundvall J, Laatikainen T, Hakala S, et al. (2008) Systematic error of serum triglyceride measurements during three decades and the effect of fasting on serum triglycerides in population studies. Clin Chim Acta 397, 55-59.
55. Hata Y & Nakajima K (2000) Life-style and serum lipids and lipoproteins. J Atheroscler Thromb 7, 177-197.
56. Wang Z, Yao T & Song Z (2010) Chronic alcohol consumption disrupted cholesterol homeostasis in rats: down-regulation of low-density lipoprotein receptor and enhancement of cholesterol biosynthesis pathway in the liver. Alcohol Clin Exp Res 34, 471-478.
57. Röhrig B, du Prel JB, Wachtlin D, et al. (2010) Sample size calculation in clinical trials: part 13 of a series on evaluation of scientific publications. Dtsch Ärztebl Int 107, 552-556.
58. Marcocci C, Kahaly GJ, Krassas GE, et al. (2011) Selenium and the course of mild Graves' orbitopathy. N Engl J Med 364, 1920-1931.